Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Value Market Research | PRODUCT CODE: 2031048

Cover Image

PUBLISHER: Value Market Research | PRODUCT CODE: 2031048

Global Psoriasis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034

PUBLISHED:
PAGES: 201 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3920
PDF & Excel (10-user License)
USD 4730
PDF & Excel (Corporate User License)
USD 7430

Add to Cart

The global psoriasis treatment market size is expected to reach USD 82.61 Billion in 2034 from USD 31.24 Billion in 2025, growing at a CAGR of 11.41 during 2026-2034.This market is evolving as healthcare systems place greater emphasis on managing chronic autoimmune conditions that affect quality of life. Psoriasis, a long-term inflammatory skin disorder, requires continuous treatment through topical therapies, systemic drugs, and biologics. Growing awareness about early diagnosis and treatment options is contributing to rising patient engagement. Healthcare providers are increasingly adopting advanced therapies that target underlying immune responses rather than just symptoms, improving treatment outcomes and long-term disease control.

Growth is supported by increasing prevalence of autoimmune diseases, advancements in biologic drug development, and rising healthcare expenditure. Biologics and targeted therapies are gaining prominence due to their effectiveness in managing moderate to severe psoriasis. Pharmaceutical companies are investing heavily in research to develop safer and more efficient treatments. Additionally, the expansion of dermatology clinics and telemedicine services is improving patient access to care. Favorable reimbursement policies in several regions are also encouraging treatment adoption.

Future prospects indicate continued innovation in personalized medicine and next-generation biologics. The development of oral therapies with fewer side effects and improved efficacy will further enhance patient compliance. Emerging markets are expected to witness increased adoption due to improving healthcare infrastructure and awareness. As research continues to advance and treatment options expand, the psoriasis treatment market is positioned for sustained growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

  • TNF Inhibitors
  • Interleukins Inhibitors
  • Others

By Type

  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Others

By Product Type

  • Biologics
  • Non-Biologics

By Route of Administration

  • Oral
  • Parenteral/Systemic
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • AbbVie Inc., Novartis AG, Johnson & Johnson Services, Inc., Pfizer Inc., LEO Pharma A/S, Merck & Co., Inc., Amgen Inc., Eli Lilly and Company, Evelo Biosciences, Inc., UCB S.A., Sun Pharmaceutical Industries Ltd.
Product Code: VMR112117972

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PSORIASIS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. TNF Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Interleukins Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PSORIASIS TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Plaque Psoriasis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Psoriatic Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PSORIASIS TREATMENT MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Product Type
  • 6.2. Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Non-Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PSORIASIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Route Of Administration
  • 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Parenteral/Systemic Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PSORIASIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL PSORIASIS TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Drug Class
    • 9.2.2 By Type
    • 9.2.3 By Product Type
    • 9.2.4 By Route Of Administration
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Drug Class
    • 9.3.2 By Type
    • 9.3.3 By Product Type
    • 9.3.4 By Route Of Administration
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Drug Class
    • 9.4.2 By Type
    • 9.4.3 By Product Type
    • 9.4.4 By Route Of Administration
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Drug Class
    • 9.5.2 By Type
    • 9.5.3 By Product Type
    • 9.5.4 By Route Of Administration
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Drug Class
    • 9.6.2 By Type
    • 9.6.3 By Product Type
    • 9.6.4 By Route Of Administration
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL PSORIASIS TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 AbbVie Inc
    • 11.2.2 Novartis AG
    • 11.2.3 Johnson & Johnson ServicesInc
    • 11.2.4 Pfizer Inc
    • 11.2.5 LEO Pharma A/S
    • 11.2.6 Merck & Co.Inc
    • 11.2.7 Amgen Inc
    • 11.2.8 Eli Lilly And Company
    • 11.2.9 Evelo BiosciencesInc
    • 11.2.10 UCB S.A
    • 11.2.11 Sun Pharmaceutical Industries Ltd
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!